| S7443 |
AP-III-a4 (ENOblock)
|
AP-III-a4 (ENOblock) is the first nonsubstrate analogue inhibitor of enolase with IC50 of 0.576 μM.
|
-
Cell Div, 2025, 20(1):23
-
J Exp Clin Cancer Res, 2023, 42(1):1
-
bioRxiv, 2023, 10.1101/2023.08.01.551011
|
|
| E1703 |
SF2312
|
SF2312 is a highly potent inhibitor of Enolase with IC50s of 37.9 nM and 42.5 nM for human recombinant ENO1 and ENO2, respectively, and also is a natural phosphonate antibiotic. SF2312 displays activity against bacteria under anaerobic conditions.
|
|
|
| E7903 |
Glucosylsphingosine
|
Glucosylsphingosine (lyso-Gb1) is a deacylated form of glucosylceramide and is also degraded by the glucocerebrosidase. This compound is a very promising, reliable and specific biomarker for monitoring Gaucher disease.
|
|
|
| E7659 |
RO-28-1675
|
RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC50 of 54 nM. This compound can be used for the research of type 2 diabetes.
|
|
|
| E7726 |
Palmitelaidic Acid
|
Palmitelaidic Acid (9-trans-Hexadecenoic acid) is the trans isomer of palmitoleic acid. Palmitoleic acid is one of the most abundant fatty acids in serum and tissue.
|
|
|
| E7729 |
AMG-3969
|
AMG-3969 is a potent glucokinase-glucokinase regulatory protein interaction (GK-GKRP) disruptor with an IC50 of 4 nM.
|
|
|
| E1028 |
POMHEX
|
POMHEX, is a potent ENO2 -specific inhibitor of enolase and a racemic mixture, a cell-permeable pivaloyloxymethyl (POM) prodrug of HEX. It is also glycolysis inhibitor and can be used for the research of cancer.
|
|
|
| S7289 |
PFK15
|
PFK15 (PFK-015) is a potent and selective 6-phosphofructo-2-kinase (PFKFB3) inhibitor with IC50 of 207 nM.
|
-
Nature, 2025, 10.1038/s41586-025-09328-w
-
Adv Healthc Mater, 2025, e2501417.
-
Cell Commun Signal, 2025, 23(1):104
|
|
| S7639 |
3PO
|
3PO (3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) is a small-molecule inhibitor of PFKFB3 with an IC50 of 22.9 μM for recombinant human PFKFB3 protein and does not inhibit PFK-1 activity. It suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.
|
-
Atherosclerosis, 2025, 405:119223
-
J Transl Med, 2024, 22(1):954
-
bioRxiv, 2023, 10.1101/2023.08.01.551011
|
|
| S8807 |
PFK158
|
PFK158 is a potent and selective inhibitor of PFKFB3. It has improved PK properties and causes ~80% growth inhibition in several mouse models of human-derived tumors.
|
-
bioRxiv, 2025, 2025.05.25.655979
-
Life Med, 2023, 2(1):lnad006
-
Nat Metab, 2022, 4(10):1287-1305
|
|